Skip to main content
NCBI home page
American Journal of Human Genetics logoLink to American Journal of Human Genetics
. 1997 Feb;60(2):305–312.

A potential role for NF1 mRNA editing in the pathogenesis of NF1 tumors.

A J Cappione 1, B L French 1, G R Skuse 1
PMCID: PMC1712412  PMID: 9012403

Abstract

Neurofibromatosis type I (NF1) is a common disorder that predisposes to neoplasia in tissues derived from the embryonic neural crest. The NF1 gene encodes a tumor suppressor that most likely acts through the interaction of its GTPase-activating protein (GAP)-related domain (GRD) with the product of the ras protooncogene. We have previously identified a site in the NF1 mRNA, within the first half of the NF1 GRD, which undergoes base-modification editing. Editing at that site changes a C to a U, thereby introducing an in-frame stop codon. NF1 RNA editing has been detected in all cell types studied, to date. In order to investigate the role played by editing in NF1 tumorigenesis, we analyzed RNA from 19 NF1 and 4 non-NF1 tumors. We observed varying levels of NF1 mRNA editing in different tumors, with a higher range of editing levels in more malignant tumors (e.g., neurofibrosarcomas) compared to benign tumors (cutaneous neurofibromas). Plexiform neurofibromas have an intermediate range of levels of NF1 mRNA editing. We also compared tumor and nontumor tissues from several NF1 individuals, to determine the extent of variability present in the constitutional levels of NF1 mRNA editing and to determine whether higher levels are present in tumors. The constitutional levels of NF1 mRNA editing varied slightly but were consistent with the levels observed in non-NF1 individuals. In every case, there was a greater level of NF1 mRNA editing in the tumor than in the nontumor tissue from the same patient. These results suggest that inappropriately high levels of NF1 mRNA editing does play a role in NF1 tumorigenesis and that editing may result in the functional equivalent of biallelic inactivation of the NF1 tumor suppressor.

Full text

PDF
305

Images in this article

307Figure 2
on p.307
308Figure 3
on p.308

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baum C. L., Teng B. B., Davidson N. O. Apolipoprotein B messenger RNA editing in the rat liver. Modulation by fasting and refeeding a high carbohydrate diet. J Biol Chem. 1990 Nov 5;265(31):19263–19270. [PubMed] [Google Scholar]
  2. Bollag G., McCormick F., Clark R. Characterization of full-length neurofibromin: tubulin inhibits Ras GAP activity. EMBO J. 1993 May;12(5):1923–1927. doi: 10.1002/j.1460-2075.1993.tb05841.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Buchberg A. M., Cleveland L. S., Jenkins N. A., Copeland N. G. Sequence homology shared by neurofibromatosis type-1 gene and IRA-1 and IRA-2 negative regulators of the RAS cyclic AMP pathway. Nature. 1990 Sep 20;347(6290):291–294. doi: 10.1038/347291a0. [DOI] [PubMed] [Google Scholar]
  4. Colman S. D., Williams C. A., Wallace M. R. Benign neurofibromas in type 1 neurofibromatosis (NF1) show somatic deletions of the NF1 gene. Nat Genet. 1995 Sep;11(1):90–92. doi: 10.1038/ng0995-90. [DOI] [PubMed] [Google Scholar]
  5. Easton D. F., Ponder M. A., Huson S. M., Ponder B. A. An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): evidence for modifying genes. Am J Hum Genet. 1993 Aug;53(2):305–313. [PMC free article] [PubMed] [Google Scholar]
  6. Greeve J., Altkemper I., Dieterich J. H., Greten H., Windler E. Apolipoprotein B mRNA editing in 12 different mammalian species: hepatic expression is reflected in low concentrations of apoB-containing plasma lipoproteins. J Lipid Res. 1993 Aug;34(8):1367–1383. [PubMed] [Google Scholar]
  7. Gutman D. H., Andersen L. B., Cole J. L., Swaroop M., Collins F. S. An alternatively-spliced mRNA in the carboxy terminus of the neurofibromatosis type 1 (NF1) gene is expressed in muscle. Hum Mol Genet. 1993 Jul;2(7):989–992. doi: 10.1093/hmg/2.7.989. [DOI] [PubMed] [Google Scholar]
  8. Gutmann D. H., Geist R. T., Rose K., Wright D. E. Expression of two new protein isoforms of the neurofibromatosis type 1 gene product, neurofibromin, in muscle tissues. Dev Dyn. 1995 Mar;202(3):302–311. doi: 10.1002/aja.1002020309. [DOI] [PubMed] [Google Scholar]
  9. Hope D. G., Mulvihill J. J. Malignancy in neurofibromatosis. Adv Neurol. 1981;29:33–56. [PubMed] [Google Scholar]
  10. Huson S. M., Compston D. A., Clark P., Harper P. S. A genetic study of von Recklinghausen neurofibromatosis in south east Wales. I. Prevalence, fitness, mutation rate, and effect of parental transmission on severity. J Med Genet. 1989 Nov;26(11):704–711. doi: 10.1136/jmg.26.11.704. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Inui Y., Giannoni F., Funahashi T., Davidson N. O. REPR and complementation factor(s) interact to modulate rat apolipoprotein B mRNA editing in response to alterations in cellular cholesterol flux. J Lipid Res. 1994 Aug;35(8):1477–1489. [PubMed] [Google Scholar]
  12. Knudson A. G., Jr Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A. 1971 Apr;68(4):820–823. doi: 10.1073/pnas.68.4.820. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Li Y., O'Connell P., Breidenbach H. H., Cawthon R., Stevens J., Xu G., Neil S., Robertson M., White R., Viskochil D. Genomic organization of the neurofibromatosis 1 gene (NF1). Genomics. 1995 Jan 1;25(1):9–18. doi: 10.1016/0888-7543(95)80104-t. [DOI] [PubMed] [Google Scholar]
  14. Metheny L. J., Cappione A. J., Skuse G. R. Genetic and epigenetic mechanisms in the pathogenesis of neurofibromatosis type I. J Neuropathol Exp Neurol. 1995 Nov;54(6):753–760. doi: 10.1097/00005072-199511000-00001. [DOI] [PubMed] [Google Scholar]
  15. Nishi T., Lee P. S., Oka K., Levin V. A., Tanase S., Morino Y., Saya H. Differential expression of two types of the neurofibromatosis type 1 (NF1) gene transcripts related to neuronal differentiation. Oncogene. 1991 Sep;6(9):1555–1559. [PubMed] [Google Scholar]
  16. Sharma P. M., Bowman M., Madden S. L., Rauscher F. J., 3rd, Sukumar S. RNA editing in the Wilms' tumor susceptibility gene, WT1. Genes Dev. 1994 Mar 15;8(6):720–731. doi: 10.1101/gad.8.6.720. [DOI] [PubMed] [Google Scholar]
  17. Skuse G. R., Cappione A. J., Sowden M., Metheny L. J., Smith H. C. The neurofibromatosis type I messenger RNA undergoes base-modification RNA editing. Nucleic Acids Res. 1996 Feb 1;24(3):478–485. doi: 10.1093/nar/24.3.478. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Uchida T., Matozaki T., Suzuki T., Matsuda K., Wada K., Nakano O., Konda Y., Nishisaki H., Nagao M., Sakamoto C. Expression of two types of neurofibromatosis type 1 gene transcripts in gastric cancers and comparison of GAP activities. Biochem Biophys Res Commun. 1992 Aug 31;187(1):332–339. doi: 10.1016/s0006-291x(05)81497-4. [DOI] [PubMed] [Google Scholar]
  19. Xu G. F., O'Connell P., Viskochil D., Cawthon R., Robertson M., Culver M., Dunn D., Stevens J., Gesteland R., White R. The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell. 1990 Aug 10;62(3):599–608. doi: 10.1016/0092-8674(90)90024-9. [DOI] [PubMed] [Google Scholar]

Articles from American Journal of Human Genetics are provided here courtesy of American Society of Human Genetics

RESOURCES